Statins in non-ischaemic cardiomyopathy: an update on our current clinical and pathophysiological understanding

Summary Statins are a cornerstone in reducing cardiovascular events. Studies show that statins are beneficial even in patients with normal or low cholesterol levels, indicating pleiotropic mechanisms of therapeutic benefit apart from their antihyperlipidemic effect. Non‐randomised, observational and...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical practice (Esher) 2011-11, Vol.65 (11), p.1156-1164
Main Authors: Verma, N., Figueredo, V. M.
Format: Article
Language:English
Subjects:
Antihypertensive Agents - therapeutic use
Arrhythmias, Cardiac - prevention & control
Biological and medical sciences
Cardiology. Vascular system
Cardiomyopathies - drug therapy
Cytokines - metabolism
Death, Sudden, Cardiac - prevention & control
Endothelium, Vascular - drug effects
General aspects
Heart
Heart Defects, Congenital - prevention & control
Heart Failure - prevention & control
Heart Valve Diseases - prevention & control
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Hypertension - prevention & control
Medical sciences
Myocarditis. Cardiomyopathies
Randomized Controlled Trials as Topic
Thrombosis - prevention & control
Ventricular Dysfunction, Left - prevention & control
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Statins are a cornerstone in reducing cardiovascular events. Studies show that statins are beneficial even in patients with normal or low cholesterol levels, indicating pleiotropic mechanisms of therapeutic benefit apart from their antihyperlipidemic effect. Non‐randomised, observational and retrospective studies suggest that statins are associated with better outcomes in patients with heart failure (HF) of both ischaemic and non‐ischaemic aetiologies. While cholesterol reduction and plaque stabilisation likely play a role in reducing cardiovascular events in ischaemic HF patients, the mechanisms underlying the benefit in non‐ischaemic HF patients is less clear. This review suggests the pleiotropic effects of statin therapy can beneficially alter the pathophysiological mechanisms underlying the clinical benefit observed in non‐ischaemic HF patients.
ISSN:1368-5031
1742-1241
DOI:10.1111/j.1742-1241.2011.02753.x